Drug Trial Radar · NCT02973776
Vasoconstriction Trial With LEO 90100 Aerosol Foam
Last checked: Nov 20, 2026Latest source record: May 9, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Dec 2016
Primary completion
Feb 2017
Study completion Feb 2017
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- First posted
- Nov 25, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Single group
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Vasoconstriction study with LEO 90100
Conditions
- Psoriasis Vulgaris
Interventions
LEO 90100 aerosol foamDrug
Dermoval®/Dermovate®Drug
DiprosoneDrug
EloconDrug
LocoidDrug
LEO 90100 foam vehicleOther
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean of two visual skin blanching scores for each treatment measured 2 hours after 16 hours application under non-occlusive conditionsTime frame: 18 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CPCAD
Nice, Cedex, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.